TY - JOUR T1 - Critical appraisal of the European Union Scientific Committee on Health, Environmental and Emerging Risks (SCHEER) <em>Preliminary Opinion on electronic cigarettes</em> JF - medRxiv DO - 10.1101/2020.11.09.20228296 SP - 2020.11.09.20228296 AU - R. O’Leary AU - R. Polosa AU - G. Li Volti AU - on behalf of the CoEHAR study group Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/11/10/2020.11.09.20228296.abstract N2 - Background In preparation for the 2021 revision of the European Union Tobacco Products Directive, the Scientific Committee on Health, Environmental and Emerging Risks (SCHEER) has posted its Preliminary Opinion on Electronic Cigarettes. They conclude that e-cigarettes only achieve a sub-optimal level of protection of human health. In this paper we provide evidence that Opinion’s conclusions are not adequately backed up by scientific evidence and totally disregard the potential health benefits of using alternative combustion-free nicotine containing products as substitute for tobacco cigarettes.Method Searches for articles were conducted in PubMed and by citation chasing in Google Scholar. Articles were also retrieved with a review of references in major publications. Primary data from World Health Organization surveys, the conclusions of reviews, and peer-reviewed non-industry studies were cited to address errors and omissions identified in the Opinion.Results The Opinion omitted reporting on the individual and population health benefits of the substitution of e-cigarettes (ENDS) for cigarette smoking. Alternative hypotheses to the gateway theory were not evaluated. Its assessment of cardiovascular risk is contradicted by numerous reviews. It exhibits biases in its statements from the measurements selected on the frequency of use. It did not report non-nicotine use. It misrepresented trends in ENDS prevalence. It over-emphasized the role of flavours in youth ENDS initiation. It did not discuss cessation in sufficient length.Conclusions For the delivery of a robust and comprehensive final report, the members of the Working Group of the Scientific Committee on Health, Environmental and Emerging Risks will need to consider (1) the potential health benefits of ENDS substitution for cigarette smoking, (2) alternative hypotheses and contradictory studies on the gateway effect, (3) its assessment of cardiovascular risk, (4) biases arising from the measurements of frequency of use, (5) non-nicotine use, (6) the role of flavours, and (7) a fulsome discussion of cessation.Competing Interest StatementRO is supported by a contract from ECLAT srl a spin-off of the University of Catania Italy as a Project Leader for a literature review research project she independently developed and submitted to the Center of Excellence for the Acceleration of Harm Reduction (CoEHAR). CoEHAR has received a grant from the Foundation for a Smoke-Free World for the research project. She declares no conflict of interest. RP is full-time employee of the University of Catania, Italy. In relation to his work in the area of tobacco control and respiratory diseases, RP has received lecture fees and research funding from Pfizer, GlaxoSmithKline, CV Therapeutics, NeuroSearch A/S, Sandoz, MSD, Boehringer Ingelheim, Novartis, Duska Therapeutics, and Forest Laboratories. He has also served as a consultant for Pfizer, Global Health Alliance for treatment of tobacco dependence, CV Therapeutics, NeuroSearch A/S, Boehringer Ingelheim, Novartis, Duska Therapeutics, Alfa-Wassermann, Forest Laboratories, ECITA (Electronic Cigarette Industry Trade Association, in the UK), Arbi Group Srl., and Health Diplomats. RP is the Founder of the Center of Excellence for the acceleration of Harm Reduction at the University of Catania (CoEHAR), which has received a grant from Foundation for a Smoke Free World to develop and carry out 8 research projects. RP is also currently involved in the following pro bono activities: scientific advisor for LIAF, Lega Italiana Anti Fumo (Italian acronym for Italian Anti-Smoking League) and Chair of the European Technical Committee for standardization on Requirements and test methods for emissions of electronic cigarettes (CEN/TC 437; WG4). GLV is full professor of biochemistry at University of Catania and he is currently chairman of the Center of Excellence for the acceleration of Harm Reduction at the University of Catania (CoEHAR), which has received a grant from the Foundation for a Smoke Free World to support 8 independent investigator-initiated research projects on tobacco harm reduction. Clinical Trialnot a clinical trialFunding StatementNo funding was received for this article.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB not requiredAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData for Tables 1, 2, 3, and 7 were extracted from the published articles cited as the source. Data for Table 4 is from the Passport database and is not publicly available. It is available only by subscription from EUROMONITOR International, London, a privately owned market research company. The company can be contacted at https://www.euromonitor.com/ Data for Tables 5 and 6 are from the Global Youth Tobacco Surveys with open access at the World Health Organization NCD Microdata Repository: https://extranet.who.int/ncdsmicrodata/index.php/home. https://www.euromonitor.com/ https://extranet.who.int/ncdsmicrodata/index.php/home BPblood pressureCI 95%confidence intervalCOPDchronic obstructive pulmonary disease ENDS electronic nicotine delivery system(s)ESPADEuropean School Survey Project on Alcohol and Other DrugsEUEuropean UnionGYTSGlobal Youth Tobacco SurveyNtotal number of participantsnsubset of participants NR not reportedNYTS USNational Youth Tobacco SurveyPATH USPopulation Assessment of Tobacco and Health Survey RR relative riskRRRrelative risk ratioUSUnited StatesWHOWorld Health Organization ER -